New bone marrow transplant program opens in Arizona

Good news for hematologic cancer patients in need of a hematopoietic stem cell transplant living in the southwestern United States.

The Virginia G. Piper Cancer Center at Scottsdale Healthcare recently announced the addition of a hematopoietic stem cell transplant cancer treatment program at the facility's new Cancer Transplant Institute.

The program is expected to attract hematologic cancer patients including those with lymphomas in desperate need of a bone marrow transplant.

Already a member of the National Marrow Transplant Program (NMDP), which allows it to perform unrelated donor transplants, the Cancer Transplant Institute at the Virginia G. Piper Cancer Center is accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) for autologous and allogeneic adult transplants.

Source: PR Newswire

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap